Literature DB >> 25825450

Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire.

Cathrine Scheepers1, Ram K Shrestha2, Bronwen E Lambson1, Katherine J L Jackson3, Imogen A Wright2, Dshanta Naicker4, Mark Goosen4, Leigh Berrie4, Arshad Ismail4, Nigel Garrett5, Quarraisha Abdool Karim6, Salim S Abdool Karim6, Penny L Moore7, Simon A Travers2, Lynn Morris8.   

Abstract

The human Ig repertoire is vast, producing billions of unique Abs from a limited number of germline Ig genes. The IgH V region (IGHV) is central to Ag binding and consists of 48 functional genes. In this study, we analyzed whether HIV-1-infected individuals who develop broadly neutralizing Abs show a distinctive germline IGHV profile. Using both 454 and Illumina technologies, we sequenced the IGHV repertoire of 28 HIV-infected South African women from the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 002 and 004 cohorts, 13 of whom developed broadly neutralizing Abs. Of the 259 IGHV alleles identified in this study, approximately half were not found in the International Immunogenetics Database (IMGT). This included 85 entirely novel alleles and 38 alleles that matched rearranged sequences in non-IMGT databases. Analysis of the rearranged H chain V region genes of mAbs isolated from seven of these women, as well as previously isolated broadly neutralizing Abs from other donors, provided evidence that at least eight novel or non-IMGT alleles contributed to functional Abs. Importantly, we found that, despite a wide range in the number of IGHV alleles in each individual, including alleles used by known broadly neutralizing Abs, there were no significant differences in germline IGHV repertoires between individuals who do and do not develop broadly neutralizing Abs. This study reports novel IGHV repertoires and highlights the importance of a fully comprehensive Ig database for germline gene usage prediction. Furthermore, these data suggest a lack of genetic bias in broadly neutralizing Ab development in HIV-1 infection, with positive implications for HIV vaccine design.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25825450      PMCID: PMC4513073          DOI: 10.4049/jimmunol.1500118

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

2.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

3.  The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.

Authors:  Elin S Gray; Maphuti C Madiga; Tandile Hermanus; Penny L Moore; Constantinos Kurt Wibmer; Nancy L Tumba; Lise Werner; Koleka Mlisana; Sengeziwe Sibeko; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

4.  Genomic screening by 454 pyrosequencing identifies a new human IGHV gene and sixteen other new IGHV allelic variants.

Authors:  Yan Wang; Katherine J Jackson; Bruno Gäeta; William Pomat; Peter Siba; William A Sewell; Andrew M Collins
Journal:  Immunogenetics       Date:  2011-01-20       Impact factor: 2.846

5.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

Review 6.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Authors:  Leonidas Stamatatos; Lynn Morris; Dennis R Burton; John R Mascola
Journal:  Nat Med       Date:  2009-08       Impact factor: 53.440

7.  Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing.

Authors:  Scott D Boyd; Eleanor L Marshall; Jason D Merker; Jay M Maniar; Lyndon N Zhang; Bita Sahaf; Carol D Jones; Birgitte B Simen; Bozena Hanczaruk; Khoa D Nguyen; Kari C Nadeau; Michael Egholm; David B Miklos; James L Zehnder; Andrew Z Fire
Journal:  Sci Transl Med       Date:  2009-12-23       Impact factor: 17.956

8.  Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease.

Authors:  Felix Breden; Christa Lepik; Nancy S Longo; Marinieve Montero; Peter E Lipsky; Jamie K Scott
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

9.  RAMICS: trainable, high-speed and biologically relevant alignment of high-throughput sequencing reads to coding DNA.

Authors:  Imogen A Wright; Simon A Travers
Journal:  Nucleic Acids Res       Date:  2014-05-26       Impact factor: 16.971

10.  Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study.

Authors:  Francois van Loggerenberg; Koleka Mlisana; Carolyn Williamson; Sara C Auld; Lynn Morris; Clive M Gray; Quarraisha Abdool Karim; Anneke Grobler; Nomampondo Barnabas; Itua Iriogbe; Salim S Abdool Karim
Journal:  PLoS One       Date:  2008-04-16       Impact factor: 3.240

View more
  36 in total

1.  Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.

Authors:  Ivan Jelcic; Benoit Combaluzier; Ilijas Jelcic; Wolfgang Faigle; Luzia Senn; Brenda J Reinhart; Luisa Ströh; Roger M Nitsch; Thilo Stehle; Mireia Sospedra; Jan Grimm; Roland Martin
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

2.  Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.

Authors:  Matthias Pauthner; Jenny Yeung; Chris Ullman; Joost Bakker; Thierry Wurch; Janice M Reichert; Fridtjof Lund-Johansen; Andrew R M Bradbury; Paul J Carter; Joost P M Melis
Journal:  MAbs       Date:  2016       Impact factor: 5.857

3.  The mouse antibody heavy chain repertoire is germline-focused and highly variable between inbred strains.

Authors:  Andrew M Collins; Yan Wang; Krishna M Roskin; Christopher P Marquis; Katherine J L Jackson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-05       Impact factor: 6.237

4.  Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor.

Authors:  David A Spencer; Delphine C Malherbe; Néstor Vázquez Bernat; Monika Ádori; Benjamin Goldberg; Nicholas Dambrauskas; Heidi Henderson; Shilpi Pandey; Tracy Cheever; Philip Barnette; William F Sutton; Margaret E Ackerman; James J Kobie; D Noah Sather; Gunilla B Karlsson Hedestam; Nancy L Haigwood; Ann J Hessell
Journal:  J Immunol       Date:  2021-01-20       Impact factor: 5.422

Review 5.  Deep sequencing and human antibody repertoire analysis.

Authors:  Scott D Boyd; James E Crowe
Journal:  Curr Opin Immunol       Date:  2016-04-08       Impact factor: 7.486

Review 6.  On being the right size: antibody repertoire formation in the mouse and human.

Authors:  Andrew M Collins; Katherine J L Jackson
Journal:  Immunogenetics       Date:  2017-12-19       Impact factor: 2.846

7.  LymAnalyzer: a tool for comprehensive analysis of next generation sequencing data of T cell receptors and immunoglobulins.

Authors:  Yaxuan Yu; Rhodri Ceredig; Cathal Seoighe
Journal:  Nucleic Acids Res       Date:  2015-10-07       Impact factor: 16.971

Review 8.  Igh Locus Polymorphism May Dictate Topological Chromatin Conformation and V Gene Usage in the Ig Repertoire.

Authors:  Amy L Kenter; Corey T Watson; Jan-Hendrik Spille
Journal:  Front Immunol       Date:  2021-05-18       Impact factor: 7.561

9.  Diversity in immunogenomics: the value and the challenge.

Authors:  Houda Alachkar; Cathrine Scheepers; Corey T Watson; Gunilla B Karlsson Hedestam; Serghei Mangul; Kerui Peng; Yana Safonova; Mikhail Shugay; Alice B Popejoy; Oscar L Rodriguez; Felix Breden; Petter Brodin; Amanda M Burkhardt; Carlos Bustamante; Van-Mai Cao-Lormeau; Martin M Corcoran; Darragh Duffy; Macarena Fuentes-Guajardo; Ricardo Fujita; Victor Greiff; Vanessa D Jönsson; Xiao Liu; Lluis Quintana-Murci; Maura Rossetti; Jianming Xie; Gur Yaari; Wei Zhang; Malak S Abedalthagafi; Khalid O Adekoya; Rahaman A Ahmed; Wei-Chiao Chang; Clive Gray; Yusuke Nakamura; William D Lees; Purvesh Khatri
Journal:  Nat Methods       Date:  2021-06       Impact factor: 47.990

Review 10.  Immunoglobulin germline gene variation and its impact on human disease.

Authors:  Ivana Mikocziova; Victor Greiff; Ludvig M Sollid
Journal:  Genes Immun       Date:  2021-06-26       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.